Compare · DXCM vs VTAK
DXCM vs VTAK
Side-by-side comparison of DexCom Inc. (DXCM) and Catheter Precision Inc. (VTAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and VTAK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 11477.5x VTAK ($2.9M).
- VTAK has been more active in the news (7 items in the past 4 weeks vs 6 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for VTAK).
- Company
- DexCom Inc.
- Catheter Precision Inc.
- Price
- -
- -
- Market cap
- $33.10B
- $2.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- 2018
- News (4w)
- 6
- 7
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest VTAK
- SEC Form 8-K filed by Catheter Precision Inc.
- SEC Form 8-K filed by Catheter Precision Inc.
- SEC Form 8-K filed by Catheter Precision Inc.
- SEC Form 8-K filed by Catheter Precision Inc.
- Catheter Precision Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Catheter Precision to Change its Name and Ticker Symbol to Flyte Aviation and “VJET” and Effect 1-for-10 Reverse Stock Split, Monday, October 5, at Market Open
- Flyte Named Official Air Travel Partner of the 34th Annual Hamptons International Film Festival
- Catheter Precision Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Catheter Precision Expands LockeT Commercialization Across Latin America Following Successful Launch in Brazil
- Flyte Partners With Christian Cowan for New York Fashion Week, Expanding Its Presence Across Global Luxury Brands